I understand it was pushed up before the stock offering but continues to climb with no real news. Did a bit of research last week but couldn't find anything.
i agree secondary at 25.18------------short covering anyone---input--???
I still don't get it. Phase I/II rare disease and valuation so high.
See value placed on Enobia (although they did have spectacular results)